Skip to main content
. 2021 Mar 24;2021(3):CD013705. doi: 10.1002/14651858.CD013705.pub2

Schildgen 2020 [C].

Study characteristics
Patient Sampling Comparative study of three Ag tests; Schildgen 2020 [A] reports full study characteristics and QUADAS
Patient characteristics and setting Comparative study of three Ag tests; Schildgen 2020 [A] reports full study characteristics and QUADAS
Index tests Comparative study of three Ag tests (no product codes reported); Schildgen 2020 [C] data relate to test [C], see Schildgen 2020 [A] and Schildgen 2020 [B] for data relate to tests [A] and [B], and for QUADAS entries.
Test name:
[A] BIOCREDIT
[B] Panbio
[C] SARS‐CoV‐2 Rapid Antigen test
Manufacturer:
[A] RapiGEN
[B] Abbott
[C] Roche
Antibody: Not stated
Antigen target: Not stated
Test method: All LFA
Samples used: BAL (n=13); throat wash (n=50, including 27 from asymptomatic)
Transport media: Not stated
Sample storage: Not stated
Test operator: Not stated; presume lab staff
Definition of test positivity: As per manufacturer
Blinding reported: Not stated
Timing of samples: Not stated
Target condition and reference standard(s) Comparative study of three Ag tests; Schildgen 2020 [A] reports full study characteristics and QUADAS
Flow and timing Comparative study of three Ag tests; Schildgen 2020 [A] reports full study characteristics and QUADAS
Comparative  
Notes